Roche's patent appeal leaves India's generic Risdiplam launch in limbo
The ongoing patent battle between Roche and Natco Pharma over Risdiplam, a crucial drug for spinal muscular atrophy, highlights the tension between protecting pharmaceutical innovation and ensuring patents have affordable access...To view the full article, register now.
Already a subscriber? Click here to view full article